Cell Therapeutics Inc. reports novel therapy for acute respiratory distress syndrome--the largest cause of mortality in patients with multiple traumatic injuries.
D000208:Acute Disease; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002986:Clinical Trials as Topic; D005230:Fatty Acids, Nonesterified / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D018384:Oxidative Stress; D010431:Pentoxifylline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010919:Placebos; D011878:Radiotherapy / Q000009:adverse effects; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood / Q000188:drug therapy* / Q000209:etiology
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D005230:Fatty Acids, Nonesterified; D010919:Placebos; C025189:lisofylline; D010431:Pentoxifylline